embecta has reached a partnership with Tidepool for the development of an automated insulin delivery (AID) system to treat type 2 diabetes (T2D) patients.
The company will use Tidepool’s diabetes management software expertise to create the AID algorithm for its closed-loop patch pump system.
This system, which received breakthrough device designation from the US Food and Drug Administration (FDA), has been designed to cater to the specific requirements of individuals living with type 2 diabetes.
Tidepool founder and CEO Howard Look said: “Building on the recent FDA clearance for Tidepool Loop, Tidepool is excited to partner with embecta to create tailored solutions for a broader user base including people with type 2 diabetes.”
First established in 2013, Tidepool offers a suite of software tools for individuals with diabetes and healthcare facilities.
These tools include Tidepool Web, Tidepool Mobile, Tidepool Uploader and Tidepool Loop.
embecta chief medical officer Henry Anhalt said: “The recent 510(k) clearance of Tidepool Loop — a fully interoperable automated insulin dosing app which started as a patient-led initiative — affirms that Tidepool’s approach to AID system development combines patient insights with a robust diabetes management solution.
“We believe that the combination of the embecta and Tidepool teams will lead to the development of a user-centric T2D AID system that fills a need for improved glucose management.”